Marc Goodman

Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock
Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know
5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing
Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know
5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing
After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers
Why This Biogen Analyst Says The FDA Could Still Approve Aducanumab

Marc Goodman Recent News

Biogen Soars As FDA Accepts Alzheimer's Drug For Review In 'Next Stage Of Aducanumab Saga'
Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's drug aducanumab — a drug for which the company halted studies at one point last year — could finally see the light of day.
Leerink Out Bullish On GW Pharma: 4 Reasons Why
Mallinckrodt Bull Turns Bear, Slashes Price Target By 66%
A Preview Of Next Week's Blue-Chip Earnings
UBS Downgraded AbbVie Shares; Here's What Changed Analysts' View
A Look At Teva's Paragard IUD Asset Sale To Cooper Companies, From Both Sides
Teva Loses Another Bull; Credit Suisse Downgrades
Earnings Watch: Apple, Tesla, Pfizer, Activision-Blizzard On Tap For Next Week
Intense Competition Pressures Eli Lilly, Leerink Downgrades
Analyst: Mallinckrodt Investors Seem To Be Pricing In Extreme Issues For Acthar
UBS Likes The Tune Of Jazz Pharma's Settlement With Hikma
Aside From The Recent Drug Failure, What Else Is Happening With Eli Lilly?
Near-Term Headwinds And Long-Term Promise For Gilead Sciences
Allergan Again A Core Holding At UBS
UBS Suspends Coverage Of Valeant Over Lack of Transparency
Some On Wall Street Still Back Valeant
Valeant's New-Old CEO: What To Know
These Four Analysts Remain Bullish On Valeant
UBS On Bristol-Myers Squibb: 'We Like This Opportunity Right Here Right Now'
Jazz Pharma Still Loved At UBS, Firm Hikes Price Target To $210
UBS Reviews ASCO, Notes Weekend Data Points From 2 Companies
UBS Says Impax 'Ahead Of Itself,' Downgrades To Sell
UBS Thinks AbbVie's Valuation Is 'Interesting'